Our Pipeline

Petosemtamab is a Biclonics^® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). Petosemtamab is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity.

Zeno is a Biclonics^® that utilizes the Merus Dock & Block^® mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 fusions (NRG1+ cancer). Through its unique mechanism of binding to HER2 and potently blocking the interaction of HER3 with its ligand NRG1 or NRG1-fusion proteins, Zeno has the potential to be particularly effective against NRG1+ cancer. In preclinical studies, Zeno potently inhibits HER2/HER3 heterodimer formation thereby inhibiting oncogenic signaling pathways, leading to inhibition of tumor cell proliferation and blocking tumor cell survival. In clinical studies, Zeno has demonstrated anti-tumor activity in multiple types of NRG1+ cancer, including NRG1+ NSCLC and NRG1+ PDAC.

MCLA-129 is an ADCC-enhanced human IgG1 Biclonics^® that binds to EGFR and c-MET. In preclinical models, MCLA-129 blocks growth and survival pathways and engages immune effector mechanisms to kill cancer cells. MCLA-129 reverses resistance to tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) cell lines and inhibits tumor growth in xenograft models of NSCLC. Merus has exclusively licensed Betta Pharmaceuticals Co. Ltd. to develop and potentially commercialize MCLA-129 in China, while Merus retains full rights ex-China.

MCLA-145 is a human IgG1 Biclonics^® T-cell agonist. MCLA-145 binds with high affinity and specificity to PD-L1 and CD137. A unique immunostimulatory profile of MCLA-145 derives from the ability to potently activate immune effector cells in the context of the tumor microenvironment while simultaneously blocking inhibitory signals in the same immune cell population.

Merus to receive potential milestones for advancement of this clinical candidate in development, and potential milestones and royalties upon commercialization, if approved.

Merus to receive potential milestones for advancement of this clinical candidate in development, and potential milestones and royalties upon commercialization, if approved.

Merus to receive potential milestones for advancement of this clinical candidate in development, and potential milestones and royalties upon commercialization, if approved.